Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Sep 2011 - Clin. Cancer Res.; 17(17):1078-0432 [PMID:21771874]
[Lesterhuis WJ] [de Vries IJ] [Schreibelt G] [Lambeck AJ] [Aarntzen EH] [Jacobs JF] [Scharenborg NM] [van de Rakt MW] [de Boer AJ] [Croockewit S] [van Rossum MM] [Mus R] [Oyen WJ] [Boerman OC] [Lucas S] [Adema GJ] [Punt CJ] [Figdor CG]

Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
Dez 2010 - Anticancer Res.; 30(12):1791-7530 [PMID:21187495]
[Lesterhuis WJ] [De Vries IJ] [Schreibelt G] [Schuurhuis DH] [Aarntzen EH] [De Boer A] [Scharenborg NM] [Van De Rakt M] [Hesselink EJ] [Figdor CG] [Adema GJ] [Punt CJ]

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.
Nov 2010 - Cancer Immunol. Immunother.:1432-0851 [PMID:21069321]
[Lesterhuis WJ] [Schreibelt G] [Scharenborg NM] [Brouwer HM] [Gerritsen MJ] [Croockewit S] [Coulie PG] [Torensma R] [Adema GJ] [Figdor CG] [de Vries IJ] [Punt CJ]

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.
Okt 2010 - :1532-1827 [PMID:20924373]
[Lesterhuis WJ] [de Vries IJ] [Aarntzen EA] [de Boer A] [Scharenborg NM] [van de Rakt M] [van Spronsen DJ] [Preijers FW] [Figdor CG] [Adema GJ] [Punt CJ]

Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment, a phase I/II study in metastatic melanoma patients.
Aug 2010 - :1078-0432 [PMID:20736326]
[Jacobs JF] [Punt CJ] [Lesterhuis WJ] [Sutmuller RP] [Brouwer HM] [Scharenborg NM] [Klasen IS] [Hilbrands LB] [Figdor CG] [de Vries IJ] [Adema GJ]

Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy.
Mrz 2010 - :1432-0851 [PMID:20204387]
[Schreibelt G] [Tel J] [Sliepen KH] [Benitez-Ribas D] [Figdor CG] [Adema GJ] [de Vries IJ]

Immunotherapy of diffuse gliomas: biological background, current status and future developments.
Sep 2009 - Brain Pathol.; 19(4):1750-3639 [PMID:19744040]
[Grauer OM] [Wesseling P] [Adema GJ]

Dendritic cell vaccines in melanoma: from promise to proof?
Apr 2008 - Crit. Rev. Oncol. Hematol.; 66(2):1040-8428 [PMID:18262431]
[Lesterhuis WJ] [Aarntzen EH] [De Vries IJ] [Schuurhuis DH] [Figdor CG] [Adema GJ] [Punt CJ]

Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.
Feb 2008 - Int. J. Cancer; 122(8):1097-0215 [PMID:18076066]
[Grauer OM] [Sutmuller RP] [van Maren W] [Jacobs JF] [Bennink E] [Toonen LW] [Nierkens S] [Adema GJ]

Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests.
Mai 2006 - Ann. Oncol.; 17(6):0923-7534 [PMID:16600979]
[Lesterhuis WJ] [de Vries IJ] [Schuurhuis DH] [Boullart AC] [Jacobs JF] [de Boer AJ] [Scharenborg NM] [Brouwer HM] [van de Rakt MW] [Figdor CG] [Ruers TJ] [Adema GJ] [Punt CJ]